Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Kotaro Yoshioka"'
Autor:
Taiki Matsubayashi, Kotaro Yoshioka, Su Su Lei Mon, Maho Katsuyama, Chunyan Jia, Takao Yamaguchi, Rintaro Iwata Hara, Tetsuya Nagata, Osamu Nakagawa, Satoshi Obika, Takanori Yokota
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 2, Pp 102161- (2024)
An increasing number of antisense oligonucleotides (ASOs) have been approved for clinical use. However, improvements of both efficacy and safety in the central nervous system (CNS) are crucial for the treatment with CNS diseases. We aimed to overcome
Externí odkaz:
https://doaj.org/article/a378cd3454e343f1a151222246ffb2f0
Autor:
Chunyan Jia, Su Su Lei Mon, Ying Yang, Maho Katsuyama, Kie Yoshida-Tanaka, Tetsuya Nagata, Kotaro Yoshioka, Takanori Yokota
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 31, Iss , Pp 182-196 (2023)
Antisense oligonucleotides (ASOs) are promising therapeutics for intractable central nervous system (CNS) diseases. For this clinical application, neurotoxicity is one of the critical limitations. Therefore, an evaluation of this neurotoxicity from a
Externí odkaz:
https://doaj.org/article/5fd83a8809054f899afbaeebed69e590
Autor:
Motohiro Suzuki, Satoru Ishibashi, Eri Iwasawa, Takahiro Oguma, Yasuhiro Saito, Fuying Li, Shinichi Otsu, Keiko Ichinose, Kotaro Yoshioka, Tetsuya Nagata, Takanori Yokota
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Brain endothelial cells (BECs) are involved in the pathogenesis of ischemic stroke. Recently, several microRNAs (miRNAs) in BECs were reported to regulate the endothelial function in ischemic brain. Therefore, modulation of miRNAs in BECs by
Externí odkaz:
https://doaj.org/article/cd3a4701aaf24ae883deb88aa6047607
Autor:
Daisuke Ono, Ken Asada, Daishi Yui, Fumika Sakaue, Kotaro Yoshioka, Tetsuya Nagata, Takanori Yokota
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 23, Iss , Pp 1360-1370 (2021)
DNA/RNA heteroduplex oligonucleotide (HDO), composed of DNA/locked nucleic acid (LNA) antisense oligonucleotide (ASO) and complementary RNA, is a next-generation antisense therapeutic agent. HDO is superior to the parental ASO in delivering to target
Externí odkaz:
https://doaj.org/article/6476e126391545d09058e588e4ffbb20
Autor:
Fuying Li, Keiko Ichinose, Satoru Ishibashi, Syunsuke Yamamoto, Eri Iwasawa, Motohiro Suzuki, Kie Yoshida-Tanaka, Kotaro Yoshioka, Tetsuya Nagata, Hideki Hirabayashi, Kaoru Mogushi, Takanori Yokota
Publikováno v:
Molecular Therapy. 31:1106-1122
Autor:
Takaaki Koide, Shintaro Mandai, Reo Kitaoka, Hisazumi Matsuki, Motoko Chiga, Kouhei Yamamoto, Kotaro Yoshioka, Yohsuke Yagi, Soichiro Suzuki, Tamami Fujiki, Fumiaki Ando, Takayasu Mori, Koichiro Susa, Soichiro Iimori, Shotaro Naito, Eisei Sohara, Tatemitsu Rai, Takanori Yokota, Shinichi Uchida
Publikováno v:
Circulation Research. 132:415-431
Background: Chronic kidney disease (CKD) accelerates vascular calcification via phenotypic switching of vascular smooth muscle cells (VSMCs). We investigated the roles of circulating small extracellular vesicles (sEVs) between the kidneys and VSMCs a
Autor:
Mitsugu Yanagidaira, Kotaro Yoshioka, Tetsuya Nagata, Shoichi Nakao, Kenichi Miyata, Takanori Yokota
Publikováno v:
Molecular Biology Reports. 50:3539-3546
Publikováno v:
The Journal of Organic Chemistry. 88:2207-2213
Autor:
Haruyasu Asahara, Atsushi Bonkohara, Masaya Takagi, Kento Iwai, Akitaka Ito, Kotaro Yoshioka, Shinki Tani, Kazuto Umezu, Nagatoshi Nishiwaki
Publikováno v:
Organic & Biomolecular Chemistry. 20:2282-2292
DEMO serves as a synthetic equivalent of dicationic acetic acid to facilitate nucleophilic introduction of two kinds of substituents via N-acylimine, which affords tryptophan homologs.
Autor:
Kie Yoshida-Tanaka, Hidetoshi Kaburagi, Kotaro Yoshioka, Naoto Arimura, Takanori Yokota, Frank Rigo, Toshiki Uchihara, Takashi Ishii, Kensuke Ihara, Kenichi Miyata, Haruka Miyata, Takeshi Wada, Kanjiro Miyata, Chrissa A. Dwyer, Punit P. Seth, Tetsuya Nagata, Rintaro Iwata Hara, Syunsuke Yamamoto, Hideki Hirabayashi, Satoe Ebihara, Tomoko Igari, C. Frank Bennett, Masaki Ohyagi, Berit Powers
Publikováno v:
Nature Biotechnology. 39:1529-1536
Achieving regulation of endogenous gene expression in the central nervous system (CNS) with antisense oligonucleotides (ASOs) administered systemically would facilitate the development of ASO-based therapies for neurological diseases. We demonstrate